DNA vs INCY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 04, 2026

DNA

54.2
AI Score
VS
DNA Wins

INCY

52.8
AI Score

Investment Advisor Scores

DNA

54score
Recommendation
HOLD

INCY

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA INCY Winner
Revenue 39.63M 4.50B INCY
Net Income -129.30M 104.13M INCY
Net Margin -326.3% 2.3% INCY
Operating Income -129.92M 290.65M INCY
ROE -30.8% 1.8% INCY
ROA -13.1% 1.4% INCY
Total Assets 990.05M 7.29B INCY
Cash 84.53M 3.28B INCY
Current Ratio 4.57 3.84 DNA

Relative Price Performance (Last 90 Days)

DNA 1M: -11.3% · 3M: +50.7% INCY 1M: +9.1% · 3M: +1.3%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.0 · Price: $10.23

INCY

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.8 · Price: $121.70

Fundamentals Snapshot

Metric DNA INCY
Market Cap — —
Forward P/E -3.5 14.1
Trailing P/E — 62.4
Revenue (TTM) — —
Revenue Growth -0.1% 0.1%
Gross Margin 0.7% 0.6%
Operating Margin -2.0% 0.3%
EPS -4.24 1.96
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.